Between 230,000 and 370,000 patients die of sepsis annually in the United States (1). The incidence of sepsis is rising (2), and despite intellectual advances in both defining and managing sepsis (3–5), mortality and long-term disability from this devastating syndrome remain unacceptably high. In addition, despite significant improvements in the understanding of the molecular underpinnings of sepsis (6), advances at the bench have not translated into advances at the bedside with well over 100 negative clinical trials and no approved therapies for sepsis beyond rapid administration of antibiotics and fluid resuscitation.
Although sepsis is commonly referred to as a single entity, both host and pathogen factors can significantly impact outcome. Chronic comorbidities are associated with a significantly worse outcome from sepsis (7). Notably, not all comorbidities are of equal importance as some play a disproportionate role (8, 9). A commonly seen comorbidity in hospitalized patients is alcohol use disorder. Alcohol use disorder affects nearly 33 million people in the United States (10), and deaths from alcohol recently reached a 35-year high (11). Notably, an estimated 20% to 40% of patients admitted to the hospital have alcohol use disorder, and up to one-third of the patients admitted to the intensive care unit (ICU) carry this diagnosis (12, 13). Importantly, patients with alcohol use disorder have more frequent admissions to the ICU, longer ICU stays, and an increased risk of death (14).
Epidermal growth factor (EGF) is a cytoprotective, trophic peptide that has been shown to improve survival following sepsis and other forms of critical illness (15–18). EGF acts via its receptor EGF-R on multiple cell types. However, the survival advantage conferred by EGF in sepsis is mediated, at least in part, through the intestinal epithelium (16). The gut is frequently referred to as “the motor” of the systemic inflammatory response syndrome, and sepsis diminishes intestinal epithelial integrity, with increases in permeability and apoptosis, combined with decreases in proliferation and villus length (19–21). In addition to improving intestinal integrity, overexpression of EGF solely in villus enterocytes of transgenic mice improves survival following sepsis, demonstrating that the intestine is sufficient and potentially necessary to mediate the beneficial effects of EGF in sepsis (16).
While there are multiple reasons why preclinical trials of sepsis have failed to translate into therapeutic gain at the bedside, one potential reason is that research using animal models is performed in young mice without comorbidities, which is not reflective of the patient population that develops sepsis. Notably, multiple agents that are effective in preclinical trials in young mice without comorbidities lose their effectiveness or become harmful in the setting of aging or pre-existing comorbidities (22). To determine if alcohol use disorder impacts the efficacy of EGF in sepsis, we randomized mice to drink water or to a model of chronic alcohol ingestion that is associated with increased mortality and intestinal injury following sepsis (23). All mice were then made septic and mice were again randomized to receive either EGF or vehicle. This study design allowed us to determine the impact of chronic alcohol ingestion in sepsis and whether EGF has the same benefits in the setting of chronic alcohol ingestion as it does in animals without pre-existing comorbidities.
MATERIALS AND METHODS
Six-week-old male FVB/N mice were purchased from a commercial vendor (Charles River Laboratories, Wilmington, Mass). After a 1-week acclimatization period, animals were randomized to receive either alcohol or water (details below) and were then watched for an additional 12 weeks before being subjected to cecal ligation and puncture (CLP, also detailed below). Following CLP, mice were followed for 1 day to 7 days depending on whether they were used for non-survival or survival experiments. Thus, animals were 19 weeks to 20 weeks old at the time of sacrifice. Experiments were performed in accordance with the National Institutes of Health Guidelines for the Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at Emory University School of Medicine (Protocol DAR-2002473-090316BN). All animals were housed in an approved university animal facility and were given free access to food and either water or alcohol throughout. Prior to CLP, all animals were given a single dose of buprenex (0.1 mg/kg, McKesson Medical, San Francisco, Calif) in an attempt to minimize animal suffering. Buprenex was redosed postoperatively as deemed appropriate by the staff of the Division of Animal Resources at Emory University. Animals were sacrificed 24 h following CLP for non-survival studies by exsanguination under deep isoflurane anesthesia. A different cohort of mice were followed for 7 days post-CLP for survival. All animals were checked twice daily to determine if they were moribund, and if they were, they were sacrificed using humane endpoints. Moribund animals were identified as follows: surgical complications unresponsive to immediate intervention (wound dehiscence, bleeding), medical conditions unresponsive to treatment including self-mutilation, severe respiratory distress, icterus, or intractable diarrhea, or clinical or behavioral signs unresponsive to appropriate intervention persisting for 1 day including significant inactivity, labored breathing, sunken eyes, hunched posture, piloerection/matted fur, one or more unresolving skin ulcers, and abnormal vocalization when handled. Animals in mortality studies that survived 7 days following CLP were sacrificed using asphyxiation by CO2.
Chronic alcohol ingestion model
Mice were randomized to receive either alcohol or water in a 1:1 ratio. Mice in the alcohol group were acclimated to alcohol by increasing the concentration from 0% to 20% (volume/volume) over a course of 2 weeks (5% v/v for 4 days, 10% v/v for 4 days, 15% v/v for 4 days) and then received 20% alcohol concentration for an additional 10 weeks for a total of 12 weeks. At the conclusion of 12 weeks of either drinking alcohol or water, mice had similar body weights and renal function (data not shown), gut integrity, and liver histology (23). Following CLP, all mice received water regardless of whether they had been randomized to the alcohol or water groups for the previous 12 weeks. The rationale behind this is to mimic the clinical scenario in which all septic patients are given hydration in the ICU but are not given alcohol in the hospital even if they have a chronic history of alcohol use.
CLP was performed according to the method of Baker et al. Under isoflurane anesthesia, a small midline abdominal incision was made. The cecum was ligated just distal to the ileocecal valve by a technique that did not result in intestinal obstruction, punctured twice with a 25-gauge needle and then gently squeezed to extrude a small amount of stool. The cecum was then replaced into the abdomen, which was closed in layers. To mimic the clinical scenario where septic patients receive fluid resuscitation and antibiotics, all animals received these treatments following CLP. Specifically, all mice received a subcutaneous injection of 1 mL of 0.9% saline postoperatively to account for insensible fluid losses that occurred during surgery. Animals that were sacrificed 24 h after CLP received two doses of ceftriaxone 50 mg/kg (Sigma-Aldrich, St. Louis, Mo) and metronidazole 30 mg/kg (Apotex Corp, Weston, Fla) given subcutaneously at 3 and 15 h postoperatively. Animals followed for survival received antibiotics every 12 h for a total of 48 h.
Systemic EGF administration
Both water-fed and alcohol-fed animals were then randomized to receive either EGF or saline vehicle. EGF (Harlan Bioproducts, Indianapolis, Ind) was given in a post-treatment fashion following CLP via intraperitoneal injections of 75 μg/kg administered twice a day (total dose of 150 μg/kg/day). EGF injections were continued twice a day until animals were sacrificed. This dosage and timing was chosen based on published work giving EGF following sepsis (15). This resulted in four groups hereafter referred to as: water (mice that drank water prior to sepsis and received vehicle after CLP), alcohol (mice that drank alcohol for 12 weeks prior to sepsis and received vehicle after CLP), water+EGF (mice that drank water prior to sepsis and received EGF after CLP), and alcohol+EGF (mice that drank alcohol prior to sepsis and received EGF after CLP).
Mice were gavaged with 0.5 mL of fluorescein isothiocyanate conjugated-dextran (FD-4, 22 mg/mL, molecular mass 4.4 kD, Sigma-Aldrich) 5 h prior to sacrifice (26–28). At the time of sacrifice, blood was collected and centrifuged at 10,000 rpm at 4oC for 10 min. Plasma (50 μL) was then diluted with an equal amount of sterile phosphate-buffered saline (pH 7.4), and the concentration of FD-4 was determined using fluorospectrometry (Synergy HT, BioTek, Winooski, Vt) at an excitation wavelength of 485 nm and an emission wavelength of 528 nm with serially diluted samples as standards. All samples and standards were run in duplicate.
Intestinal protein expression analysis
At the time of sacrifice, segments of jejunum were snap-frozen in liquid nitrogen and stored at −80oC. These were subsequently weighed and added to ×5 volume-to-weight ice-cold lysis buffer (50 mM Tris HCl; 10 mM EDTA; 100 mM NaCl; 0.5% Triton X-100) containing the commercially available protease inhibitor mix Complete Mini, EDTA-free (Roche, Indianapolis, Ind) for homogenization. After 30 min on ice, homogenates were centrifuged at 10,600 × g for 10 min at 4oC. Sample total protein concentration was determined on the supernatant using the Pierce 660 nm protein assay (Thermo Scientific, Rockford, Ill). For protein expression analysis, 40 μg of protein was added to an equal volume of Laemlli buffer and heated for 5 min at 95oC. Protein was separated by the SDS-PAGE method on 4% to 20% gradient stain-free gels (BioRad, Hercules, Calif) at 120 V for ∼50 min. The stain-free gel and proteins were activated for 5 min and the protein was transferred to polyvinylidene difluoride membranes using a semiwet method via Transblot Turbo (BioRad) at 25 V for 10 min. Membranes were blocked in 5% non-fat milk in TBS with 0.1% Tween-20 for 1 h at room temperature. Membranes were then incubated overnight at 4oC with rabbit anti-claudin 1 (1 μg/mL, Invitrogen, Camarillo, Calif), rabbit anti-claudin 2 (1:1,000, Abcam, Cambridge, Mass), rabbit anti-claudin 3 (1 μg/mL, Invitrogen), rabbit anti-claudin 4 (1 μg/mL, Invitrogen), rabbit anti-claudin 5 (1 μg/mL, Invitrogen), rabbit anti-claudin 8 (1 μg/mL, Invitrogen), rabbit anti-occludin (3 μg/mL, Invitrogen), rabbit anti-JAM-A (1 μg/mL, Invitrogen), rabbit anti-Bax (1:1,000, Cell Signaling Technologies, Danvers, Mass), or rabbit anti-Bcl-2 (1:1,000, Cell Signaling Technologies). After membranes were washed, they were incubated at room temperature for 1 h in anti-rabbit secondary antibody linked to horseradish peroxidase (1:1,000, Santa Cruz Biotechnology, Santa Cruz, Calif). Proteins were detected with a chemiluminescent system (GE Healthcare, Buckinghamshire, UK) and visualized with a charged coupled device (ChemiDoc Touch, BioRad). Resulting bands were analyzed using intensity quantification software (ImageLab 5.2, BioRad). Linear dynamic detection range with stain-free technology was used for lane protein normalization and comparisons (24). Data is presented as relative protein expression compared with water mice.
Intestinal epithelial apoptosis
Apoptotic cells in the crypts were quantified by two complementary methods: morphologic analysis via hematoxylin & eosin (H&E)-staining and functional analysis via active caspase-3 staining (25). For both methods, apoptotic cells were quantified in 100 contiguous well-oriented crypt-villus units per animal by an examiner blinded to sample identity. Apoptotic cells were identified on H&E-stained jejunal sections by characteristic nuclear condensation and fragmentation. For active caspase-3 staining, jejunal sections were deparaffinized, rehydrated, and incubated in 3% hydrogen peroxide for 10 minutes. Slides were then immersed in Antigen Decloaker (Biocare Medical, Concord, Calif) and heated in a pressure cooker to facilitate antigen retrieval for 45 minutes. Following this, sections were blocked with 20% goat serum (Vector Laboratories, Burlingame, Calif), and incubated with rabbit polyclonal anti-active caspase-3 (1:100; Cell Signaling Technology) overnight at 4oC. Sections were then incubated with goat anti-rabbit biotinylated secondary antibody (1:200; Vector Laboratories) for 30 min at room temperature, followed by Vectastain Elite ABC reagent (Vector Laboratories) for an additional 30 min and developed with diaminobenzidine followed by hematoxylin counterstaining.
Ninety minutes prior to sacrifice, mice received an intraperitoneal injection of 5-bromo-2’deoxyuridine (BrdU, 5 mg/mL diluted in 0.9% saline; Sigma) to label crypt cells in S-phase. Intestinal sections were subsequently deparaffinized, rehydrated, incubated in hydrogen peroxide, immersed in Antigen Decloaker and heated in a pressure cooker. Sections were then blocked for 30 min with Protein Block (Dako, Carpinteria, Calif) and incubated with rat monoclonal anti-BrdU (1:500; Accurate Chemical & Scientific, Westbury, NY) overnight at 4oC. After being incubated at room temperature with goat anti-rat secondary antibody (1:500; Accurate Chemical & Scientific) for 30 min, sections were incubated with streptavidin-horseradish peroxidase (1:500; Dako) for 30 min and developed with diaminobenzidine, followed by counterstaining with hematoxylin. Jejunal S-phase crypt cells were quantified in 100 contiguous well-oriented crypt-villus units by an examiner blinded to sample identity.
Intestinal villus length
Villus length was measured on H&E-stained sections as the distance in micrometers from the crypt neck to the villus tip in 12 well-oriented jejunal villi per animal using Image J software (National Institutes of Health, Bethesda, Md) by an examiner blinded to sample identity.
Blood taken at the time of sacrifice was centrifuged at 10,600 × g for 10 min. Cytokine concentrations were determined on the resultant serum using a multiplex cytokine assay kit (Bio-Rad) according to manufacturer protocol. All samples were run in duplicate.
Lung wet to dry weight and histopathology
The left lung from each mouse was harvested and immediately weighed to determine a “wet” weight. After drying in an oven at 115oC for 24 h, the tissue was reweighed to establish a dry weight, and a ratio of weight to dry weight was calculated. A separate cohort of animals had lung tissue sectioned and stained using H&E. Histopathologic assessment of lung injury was performed by an examiner blinded to sample identity.
Data were analyzed using the statistical software program Prism 6.0 (GraphPad, San Diego, Calif) and are presented as mean ± SEM. Data sets were evaluated for a Gaussian distribution using the D’Agostino–Pearson omnibus normality test. Multiple group comparisons were done with one-way analysis of variance followed by the Tukey post-test for data that was normally distributed. If data sets were not normally distributed, comparisons were done with the Kruskal–Wallis non-parametric one-way analysis of variance followed by the Dunn post-test. Survival was analyzed via the Log-rank test. A P value of <0.05 was considered to be statistically significant in all studies.
Effect of EGF on mortality from sepsis with and without chronic alcohol ingestion
Initial comparisons were made between animals with chronic alcohol ingestion for 12 weeks prior to the onset of sepsis and mice that drank water during the same time period prior to the onset of sepsis. Mice were then randomized to receive EGF or vehicle following CLP. Water+EGF mice had a lower 7-day mortality following CLP than water mice (18% vs. 55%, Fig. 1). Alcohol+EGF mice had a lower 7-day mortality following CLP than alcohol mice (48% vs. 79%). Notably while EGF improved mortality in alcohol mice to a level similar to water mice, mortality was significantly higher in alcohol+EGF mice compared with water+EGF mice.
Effect of alcohol and EGF on intestinal permeability and tight junction protein expression following sepsis
Subsequent mechanistic experiments were performed only on water, alcohol, and alcohol+EGF mice. The rationale behind this experimental design was that this allowed an assessment of the impact of alcohol in sepsis (water vs. alcohol) and the impact of EGF in sepsis superimposed on chronic alcohol ingestion (alcohol vs. alcohol+EGF). We did not include water+EGF mice in subsequent experiments in an effort to minimize the number of animals used since we have already published extensively comparing septic water vs. water+EGF mice (15–17).
Alcohol mice had higher serum levels of FD-4 5 h after oral gavage compared with water mice (Fig. 2A). Serum levels of FD-4 were decreased in alcohol+EGF mice compared with alcohol mice, bringing levels of intestinal permeability to similar levels seen in water mice.
To determine potential mechanisms through which EGF improved intestinal permeability, western blots were performed on intestinal tight junction proteins. Claudin 5 expression decreased significantly in alcohol mice compared with water mice (Fig. 2B). However, claudin 5 levels increased in alcohol+EGF mice compared with alcohol mice, similar to levels seen in water mice. Alcohol had no impact on JAM-A expression, as levels were similar in water and alcohol mice (Fig. 2C). However, EGF administration led to increased levels of JAM-A, as protein levels were higher in alcohol+EGF mice than alcohol mice. Expression of claudin 1, 2, 3, 4, 8, and occludin were comparable in water, alcohol and alcohol+EGF mice (data not shown).
Effect of alcohol and EGF on intestinal epithelial apoptosis following sepsis
Intestinal epithelial apoptosis was higher in alcohol mice than water mice whether assayed by H&E (Fig. 3, A and B) or active caspase 3 (Fig. 3, C and D). In contrast, EGF administration decreased gut apoptosis, as alcohol+EGF mice had lower levels of intestinal cell death compared to alcohol mice. To understand potential mechanisms responsible for alterations in intestinal apoptosis with both alcohol and EGF, western blot analysis of jejunal protein expression was performed for the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2. Bax levels were unaffected by either alcohol or EGF as levels were similar in water, alcohol and alcohol+EGF mice (Fig. 4A). In contrast, Bcl-2 expression was decreased 2.5-fold in alcohol mice compared with water mice (Fig. 4B) while EGF administration increased Bcl-2 levels in alcohol+EGF mice. The ratio of Bax/Bcl-2 is often used as a rheostat for cellular survival (26). The Bax/Bcl-2 ratio was increased in alcohol mice compared with water mice (Fig. 4C), while EGF administration decreased this ratio in alcohol+EGF mice.
Effect of alcohol and EGF on villus length and crypt proliferation following sepsis
Villus length was decreased in alcohol mice compared with water mice (Fig. 5). EGF administration increased villus length in alcohol+EGF mice. Crypt proliferation was similarly decreased in alcohol mice compared with water mice (Fig. 6). EGF administration increased levels of crypt proliferation, as alcohol+EGF mice had higher levels of S-phase cells than alcohol mice; however, EGF was unable to restore crypt proliferation in alcohol+EGF levels to levels seen in water mice.
Effect of alcohol and EGF on circulating cytokines following sepsis
Both the anti-inflammatory cytokine interleukin 10 (IL-10) and the pro-inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1), were markedly increased in alcohol mice compared with water mice (Fig. 7, A and B, Table 1). EGF administration decreased levels of both of these cytokines in alcohol+EGF mice. The pro-inflammatory cytokine tumor necrosis factor (TNF) was not affected by alcohol (Fig. 7C, Table 1). However, administration of EGF lowered TNF as cytokine levels were lower in alcohol+EGF mice than alcohol mice. Neither alcohol nor EGF impacted levels of IL-1β, IL-2, IL-6, or IFN-γ (Table 1).
EGF improved survival when administered following CLP to mice with chronic alcohol ingestion prior to the onset of sepsis. This survival benefit was associated with an improvement in multiple facets of intestinal integrity including permeability, apoptosis, villus length, and proliferation. Further, EGF decreased some (but not all) pro- and anti-inflammatory cytokines without impacting lung injury in septic mice following chronic alcohol ingestion. The survival benefit conferred by EGF in sepsis was similar in both alcohol and water mice in terms of absolute percentage (31% and 37% respectively). However, mortality was significantly higher in alcohol+EGF mice compared with water+EGF mice demonstrating that the efficacy of EGF in sepsis is blunted in the setting of this pre-existing comorbidity, since it cannot fully overcome the detrimental effects of chronic alcohol ingestion.
The results presented herein examine two complementary comparisons—the impact of EGF in the setting of chronic alcohol ingestion prior to sepsis (alcohol vs. alcohol+EGF) and the impact of alcohol alone prior to sepsis (water vs. alcohol). While it is not possible for ICU providers to alter a patient's pre-existing alcohol use disorder, the experimental design helps to clarify what impact this comorbidity could potentially have in critical illness. In order to put the results into context, it is important to emphasize first that the control group in all experiments (water mice) already had significant abnormalities in every variable examined compared with unmanipulated hosts. Water mice were animals that had free access to drinking water both before and after CLP, and as such, are representative of 18-week-old inbred septic mice. Multiple previous studies have shown that sepsis induces abnormalities in multiple facets of intestinal integrity (permeability, apoptosis, proliferation, villus length) and cytokine levels (19, 21), although the presence of lung injury in CLP is more controversial (27).
EGF administration following CLP in mice with chronic alcohol ingestion markedly improved intestinal integrity. This is consistent with prior studies in mice that drank water prior to sepsis that subsequently received systemic EGF (15). Tight junction proteins are known to be affected by sepsis, alcohol, and EGF. CLP, in isolation, increases intestinal permeability. This is associated with increases in jejunal claudin 2 and JAM-A as well as decreases in claudin 5 and occludin in FVB/N mice (the same strain used in this study) (28). In contrast, localization (but not levels) of claudins 1, 3, 4, 5, and 8 is all altered in colonic tight junctions following CLP in C57Bl/6 mice (29). Next, ZO-1 and occludin are decreased in septic alcohol mice compared with septic water mice (23). Additionally, intestine-specific overexpression of EGF normalizes sepsis-induced increases in claudin 2 (16). In this study, EGF decreased intestinal permeability in alcohol mice and this was associated with an increase in the tight junction proteins claudin 5 and JAM-A. Previous studies have shown that JAM-A-deficient mice have an increase in intestinal barrier dysfunction. Thus, the increase in intestinal JAM-A expression in alcohol+EGF mice may confer a protective effect and improve intestinal barrier function. Of note, the mechanisms through which EGF improves sepsis-induced hyperpermeability are different in alcohol mice compared with water mice given the same agent at the same dose. Together, these findings suggest that control of intestinal permeability via tight junction alterations is highly complex and differentially regulated in sepsis, alcohol, and via EGF since even the same drug (EGF) can have differing effects on the tight junction depending on baseline comorbidities.
EGF also decreased sepsis-induced intestinal epithelial apoptosis in alcohol mice. This was associated with an increase in Bcl-2 expression without a change in Bax expression, leading to a decrease in the Bax/Bcl-2 ratio. The decrease in sepsis-induced intestinal apoptosis is consistent with previous studies giving EGF—either systemically or in an intestine-specific manner—to water mice subjected to either CLP or Pseudomonas aeruginosa pneumonia (15–17). EGF signaling has previously been shown to prevent apoptosis by altering the balance of Bcl-2 family members in the mitochondrial pathway of cell death. However, EGF has also been shown to alter extrinsic death receptor pathways when given to water-fed septic mice, suggesting that the control of apoptosis is also regulated via a complicated collection of signaling outputs (15).
EGF-R is expressed on multiple cell types, and we therefore made a prehoc determination to study whether there were effects of EGF outside the intestine. EGF decreased systemic levels of IL-10, MCP-1, and TNF in alcohol mice. Of note, transactivation of EGF-R protects intestinal epithelial cells from TNF-induced apoptosis, suggesting a potential mechanistic link between systemic cytokines and gut apoptosis (30, 31). Both alcohol and sepsis independently increase serum cytokines, although both alcoholic and nonalcoholic septic patients have similar inflammatory responses (32). The impact of EGF found herein contrasts with water-fed mice subjected to P aeruginosa pneumonia-induced sepsis, where EGF did not impact serum cytokines (17). This also contrasts with water-fed mice with intestinal overexpression of EGF subjected to CLP, which similarly did not induce any change in systemic cytokines. However, our results are consistent with findings that EGF decreases hepatic levels of TNF and IL-10 in unmanipulated animals following chronic alcohol ingestion (33).
We also examined potential extra-intestinal effects of EGF in lung tissue and did not see any differences in pulmonary edema or injury with either alcohol or following EGF administration (data not shown). The rationale for examining lungs was that EGF improves endotoxin-induced lung injury in rabbits (34). Of note, the degree of lung injury induced by sepsis in mice is controversial, with a recent study demonstrating that CLP does not cause lung damage (27). Additionally, although alcohol increases susceptibility of the lungs to secondary insults such as acute respiratory distress syndrome (35), alcohol does not impact lung wet to dry ratio or pulmonary histology when superimposed on sepsis, although it does increase pulmonary myeloperoxidase levels and bronchoalveolar lavage cytokines (23).
This study has a number of limitations. The decision to initiate EGF immediately following the onset of sepsis models the ideal clinical scenario where sepsis is identified and very rapidly treated; however, these conditions are almost impossible to replicate in patients in whom delays in presentation and delays in management are common. Initiating EGF at a later timepoint might have offered additional insights. Additionally, animals were only sacrificed at a single timepoint (24 h). It is likely that a timecourse where samples were taken at multiple different timepoints following the onset of sepsis would have yielded additional mechanistic insights. Next, only male animals were used. While this experimental design was common when the experiments were performed (2012–2015), the NIH has subsequently released policies related to rigor and reproducibility which emphasize that both genders should be used, and the use of a single gender limits the generalizability of our results (36). In addition, outside survival experiments, we chose not to include a water+EGF group. This decision was made to minimize the number of animals used in experiments since we have already published extensively on water+EGF in sepsis. To verify that published results are reproducible, it would have been reasonable to repeat these experiments here although this point requires balancing a desire to reduce animal use with reproducibility. It should be noted that the survival curve comparing water to water+EGF in sepsis (Fig. 1) reproduces published work comparing these two groups (15) and the decision to not include water+EGF mice in mechanistic studies was taken only when we demonstrated that at least one major element of the response to EGF in sepsis was reproducible. Finally, while intestine-specific effects have been demonstrated to be sufficient for EGF to confer a survival advantage in mice that drink water prior to CLP, it is likely that systemic EGF had additional extra-intestinal effects not examined in this study in mice with chronic alcohol ingestion.
Despite these limitations, this study demonstrates that systemic administration of EGF improves survival in septic mice with a history of chronic alcohol ingestion. However, EGF is unable to improve survival to the same level as when EGF is given to septic mice without a history of drinking alcohol, implying that both EGF and chronic alcohol ingestion play a role in mediating mortality. This suggests that EGF may represent a potential novel therapeutic agent in the treatment of sepsis, but comorbid conditions may play a role in impacting both its efficacy and its mechanism of action.
1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis
in the United States. Crit Care Med
2. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis
3. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis
and septic shock (sepsis
4. Seymour CW, Coopersmith CM, Deutschman CS, Gesten F, Klompas M, Levy M, Martin GS, Osborn TM, Rhee C, Warren DK, et al. Application of a framework to assess the usefulness of alternative sepsis
criteria. Crit Care Med
2016; 44 3:e122–e130.
5. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving sepsis
campaign: international guidelines for management of severe sepsis
and septic shock: 2012. Crit Care Med
2013; 41 2:580–637.
6. Hotchkiss RS, Monneret G, Payen D. Sepsis
-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol
2013; 13 12:862–874.
7. Remick DG. Do not get sick when you are sick: the impact of comorbid conditions. Crit Care Med
2004; 32 10:2147–2148.
8. Mittal R, Wagener M, Breed ER, Liang Z, Yoseph BP, Burd EM, Farris AB III, Coopersmith CM, Ford ML. Phenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancy. PLoS One
2014; 9 5:e93523.
9. Turnbull IR, Clark AT, Stromberg PE, Dixon DJ, Woolsey CA, Davis CG, Hotchkiss RS, Buchman TG, Coopersmith CM. Effects of aging on the immunopathologic response to sepsis
. Crit Care Med
2009; 37 3:1018–1023.
10. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, et al. Epidemiology of DSM-5 alcohol
use disorder: results from the national epidemiologic survey on alcohol
and related conditions III. JAMA Psychiatry
2015; 72 8:757–766.
11. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep
2016; 64 (50–51):1378–1382.
12. de WM, Wan SY, Gill S, Jenvey WI, Best AM, Tomlinson J, Weaver MF. Prevalence and impact of alcohol
and other drug use disorders on sedation and mechanical ventilation: a retrospective study. BMC Anesthesiol
13. Smothers BA, Yahr HT, Ruhl CE. Detection of alcohol
use disorders in general hospital admissions in the United States. Arch Intern Med
2004; 2164 7:749–756.
14. Delgado-Rodriguez M, Gomez-Ortega A, Mariscal-Ortiz M, Palma-Perez S, Sillero-Arenas M. Alcohol
drinking as a predictor of intensive care and hospital mortality in general surgery: a prospective study. Addiction
2003; 98 5:611–616.
15. Clark JA, Clark AT, Hotchkiss RS, Buchman TG, Coopersmith CM. Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis
2008; 30 1:36–42.
16. Clark JA, Gan H, Samocha AJ, Fox AC, Buchman TG, Coopersmith CM. Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. Am J Physiol Gastrointest Liver Physiol
2009; 297 3:G471–G479.
17. Dominguez JA, Vithayathil PJ, Khailova L, Lawrance CP, Samocha AJ, Jung E, Leathersich AM, Dunne WM, Coopersmith CM. Epidermal growth factor improves survival and prevents intestinal injury in a murine model of Pseudomonas aeruginosa
2011; 236 4:381–389.
18. Berlanga J, Lodos J, Lopez-Saura P. Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF
) in burned rodents. Burns
2002; 28 5:435–442.
19. Mittal R, Coopersmith CM. Redefining the gut as the motor of critical illness. Trends Mol Med
2014; 20 4:214–223.
20. Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the “motor” of critical illness. Shock
2007; 28 4:384–393.
21. Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ dysfunction in critical illness. Crit Care Clin
2016; 32 2:203–212.
22. Liang Z, Xie Y, Dominguez JA, Breed ER, Yoseph BP, Burd EM, Farris AB, Davidson NO, Coopersmith CM. Intestine-specific deletion of microsomal triglyceride transfer protein increases mortality in aged mice. PLoS One
2014; 9 7:e101828.
23. Yoseph BP, Breed E, Overgaard CE, Ward CJ, Liang Z, Wagener ME, Lexcen DR, Lusczek ER, Beilman GJ, Burd EM, et al. Chronic alcohol
ingestion increases mortality and organ injury in a murine model of septic peritonitis. PLoS One
2013; 8 5:e62792.
24. Gilda JE, Gomes AV. Western blotting using in-gel protein labeling as a normalization control: stain-free technology. Methods Mol Biol
25. Vyas D, Robertson CM, Stromberg PE, Martin JR, Dunne WM, Houchen CW, Barrett TA, Ayala A, Perl M, Buchman TG, et al. Epithelial apoptosis
in mechanistically distinct methods of injury in the murine small intestine. Histol Histopathol
2007; 22 6:623–630.
26. Perrone EE, Jung E, Breed E, Dominguez JA, Liang Z, Clark AT, Dunne WM, Burd EM, Coopersmith CM. Mechanisms of methicillin-resistant Staphylococcus aureus pneumonia-induced intestinal epithelial apoptosis
2012; 38 1:68–75.
27. Iskander KN, Craciun FL, Stepien DM, Duffy ER, Kim J, Moitra R, Vaickus LJ, Osuchowski MF, Remick DG. Cecal ligation and puncture
-induced murine sepsis
does not cause lung injury. Crit Care Med
2013; 41 1:154–165.
28. Yoseph BP, Klingensmith NJ, Liang Z, Breed ER, Burd EM, Mittal R, Dominguez JA, Petrie B, Ford ML, Coopersmith CM: Mechanisms of intestinal barrier dysfunction in sepsis
29. Li Q, Zhang Q, Wang C, Liu X, Li N, Li J. Disruption of tight junctions during polymicrobial sepsis
in vivo. J Pathol
2009; 218 2:210–221.
30. Feng Y, Teitelbaum DH. Epidermal growth factor/TNF-alpha transactivation modulates epithelial cell proliferation
in a mouse model of parenteral nutrition. Am J Physiol Gastrointest Liver Physiol
2012; 302 2:G236–G249.
31. Yamaoka T, Yan F, Cao H, Hobbs SS, Dise RS, Tong W, Polk DB. Transactivation of EGF
receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis
. Proc Natl Acad Sci U S A
2008; 105 33:11772–11777.
32. Santolaria F, Rodriguez-Lopez C, Martin-Hernandez B, Aleman-Valls MR, Gonzalez-Reimers E, Alonso-Socas MD, Ros R, Vina JJ. Similar inflammatory response in alcoholic and non-alcoholic sepsis
patients. Eur Cytokine Netw
2011; 22 1:1–4.
33. Chen YL, Peng HC, Hsieh YC, Yang SC. Epidermal growth factor improved alcohol
-induced inflammation in rats. Alcohol
2014; 48 7:701–706.
34. Yang B, Huang W, Han J, Liang Z. Study of the role of epidermal growth factor on lung fluid transport in rabbits with acute lung injury caused by endotoxin. Exp Ther Med
2012; 4 4:611–614.
35. Simet SM, Sisson JH. Alcohol
's effects on lung health and immunity. Alcohol Res
2015; 7 2:199–208.
Keywords:© 2017 by the Shock Society
Alcohol; apoptosis; cecal ligation and puncture; cytokine; EGF; permeability; proliferation; sepsis